I dont understand. If the FDA wants to incentivize private companies to update the research on old drugs, why dont they just pay them to do it (AND not make the payment contingent on finding the drug marketable as this appears to do)? Obviously nobody knows the true value of new research on old drugs, but giving private companies blank checks to insurer's bank accounts doesnt seem like the best method to go about it.